Ceftazidime for Injection
- FOB Price:Get Latest Price >
- Min.Order:50000 Vial(s)
- Production Capacity:100 millions
- Payment Terms:L/C , T/T
- Favorite
Business Type:Trader
Country/Region:China
Ddu Verified
HOT Rank
Newlystar (Ningbo) Medtech Co., Ltd.
We only export finished medicines. We are a professional trading company, if you must make deal with manufacturer, please find manufacturer directly.
We export to Europe, to Latin American, to Asia, to Africa. We have clients in more than 30 countries.
Each year, we have big deal with a lot manufacturers in China, because the quantity is big, our price is competitive.
And to make our business longer and stable, we only deal with manufacturers with good quality.
We have a quality department dealing with registration dossier and help manufacturers pass higher GMP inspection. We are the best one in China in this issue.
Above are features of Newlystar.
If you want read more information about our company, please go ahead. But usually, offical company introduction, doesn't have many useful information.(That is my personal opinion.)
Newlystar Medtech cooperate with state of the art facilities in China and export medicines to 30+ countries worldwide. Include East Europe, Central and southeast Asia, Latin America, Africa etc. We also contract manufacture for European companies.
Newlystar-Medtech is a well established and professional supplier of Finished Pharmaceutical, Active Pharmaceutical Ingredient(API) and Medical Devices. With a proven track record of passed years, Newlystar-Medtech has been recognized by her customers as a high-quality and reliable supplier not only on products, but also on assistance for audit and improvement of GMP level, quality management system, EHS management system and registration dossier support, etc.
The essence of Newlystar-Medtech's activites, is a commitment to her customers with professional service and high-quality products with effective cost and innovative solutions. All pharmacists work in Newlystar-Medtech like a bridge link the customers and Chinese manufacturers, especially, their professional working is to make the formulation manufacturers who is familiar with Chinese Pharmacopoeia to understand well the international requirement, to ensure the success of customers.
The advantages on professional working and strongly representative base on first-class manufacturing partners in China, enable Newlystar-Medtech to provide her customers with a wide range and high-tech products, best services and capabilities for their actions in tender, distributing and improvement in their national healthcare system. Newlystar-Medtech also dedicates herself to sourcing quality medical products for Chinese market.
Services and capabilities include:
1. Sourcing quality manufacturer
2. Contract manufacturing;
3. Conduct audits to suppliers (pharmaceutical plants);
4. Consultation on audit and improvement of GMP level, quality management system and EHS management system;
5. Regulatory support, registration dossier working;
Newlystar Medtech, your professional one-stop China Souring Partner.
Business Type:Trader
Country/Region:China
Ddu Verified
HOT Rank
Product : Ceftazidime for Injection
Specification : 0.5g; 0.75g; 1.0g; 1.5g; 2.0g
Standard : BP, USP
Description:
Semisynthetic, broad-spectrum antibacterial derived from cephaloridine and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
Indication
For the treatment of patients with infections caused by susceptible strains of organisms in the following diseases: lower respiratory tract infections,skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecologic infections, intra abdominal infections (including peritonitis), and central nervous system infections (including meningitis).
Pharmacodynamics
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic for parenteral administration. Ceftazidime is bactericidal in action exerting its effect by inhibition of enzymes responsible for cell-wall synthesis, primarily penicillin binding protein 3 (PBP3). A wide range of gram-negative organisms is susceptible to ceftazidime in vitro, including strains resistant to gentamicin and other aminoglycosides. In addition, ceftazidime has been shown to be active against gram-positive organisms. It is highly stable to most clinically important beta-lactamases, plasmid or chromosomal, which are produced by both gram-negative and gram-positive organisms and, consequently, is active against many strains resistant to ampicillin and other cephalosporins. Ceftazidime has activity against the gram-negative organisms Pseudomonas and Enterobacteriaceae. Its activity against Pseudomonas is a distinguishing feature of ceftazidime among the cephalosporins.
Mechanism of action
The bactericidal activity of ceftazidime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).